Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Placebo-controlled double-blind comparative study of ME2112 in patients with acute exacerbation of schizophrenia (Phase III)

Next Previous
Trial Profile

Placebo-controlled double-blind comparative study of ME2112 in patients with acute exacerbation of schizophrenia (Phase III)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Meiji Seika Pharma

    • Most Recent Events

    • 06 Sep 2019 Primary endpoint (Mean change in Positive and Negative Symptoms Scale (PANSS) total score in 6-week treatment) has not been met, according to a RaQualia Pharma media release.
    • 06 Sep 2019 Status changed to completed, according to a RaQualia Pharma
    • 06 Sep 2019 According to a RaQualia Pharma media release, Meiji is conducting an in-depth, detailed analysis of the results observed in this study, including additional data on efficacy endpoints in order to determine the future development plans of ziprasidone.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top